GXP Auditing Services provides auditing services to help life science companies ensure compliance and quality across the product lifecycle. This includes audits of manufacturing facilities, suppliers, clinical trials, laboratories, and pharmacovigilance activities to evaluate adherence to good practices. Life science companies face increasing regulation and financial pressures, so these audits help manage risk and identify areas for improvement. GXP Auditing Services has experienced auditors who can independently assess clinical programs to provide due diligence for companies considering in-licensing products.
Process Validation Presentation from BioTechLogicPeter Dellva
Exploring Manufacturing Process Validation - BioTechLogic, Inc. is a biopharmaceutical manufacturing and CMC consulting firm with strategic and practical/hands-on experience that helps clients bring their products to market quickly and successfully by augmenting and optimizing an organization’s technical, manufacturing, analytical, and regulatory resources.
Our technical expertise resides in a wide range of biological and oligonucleotide products including recombinant proteins, vaccines and blood products. Through the combined expertise and knowledge of our staff, we have developed proven methodologies and approaches for providing reliable and dependable services in the following areas:
Process Development and Quality by Design (QbD) including:
Design of Experiments (DOE)
Development Reports
Critical Process Parameter Evaluation
Technology Implementation, Transfer and Scale-up
On-site third party contract manufacturing support
BioAnalytical Services
Process Validation
Biotechnology Project Management
Quality Assurance
Regulatory Submissions
PAI Inspection Readiness (FDA Pre-Approval Inspection Readiness)
Process Validation Presentation from BioTechLogicPeter Dellva
Exploring Manufacturing Process Validation - BioTechLogic, Inc. is a biopharmaceutical manufacturing and CMC consulting firm with strategic and practical/hands-on experience that helps clients bring their products to market quickly and successfully by augmenting and optimizing an organization’s technical, manufacturing, analytical, and regulatory resources.
Our technical expertise resides in a wide range of biological and oligonucleotide products including recombinant proteins, vaccines and blood products. Through the combined expertise and knowledge of our staff, we have developed proven methodologies and approaches for providing reliable and dependable services in the following areas:
Process Development and Quality by Design (QbD) including:
Design of Experiments (DOE)
Development Reports
Critical Process Parameter Evaluation
Technology Implementation, Transfer and Scale-up
On-site third party contract manufacturing support
BioAnalytical Services
Process Validation
Biotechnology Project Management
Quality Assurance
Regulatory Submissions
PAI Inspection Readiness (FDA Pre-Approval Inspection Readiness)
A case study - Implementation of smart test practices improves test coverage by 50% and adherence to regulatory compliance in all product releases enables STAG to gain
the trust and assist in all FDA audit of a leading compliance eLearning solutions provider.
Qms NATIONAL ACCREDITATION BOARD FOR TESTING AND CALIBRATION LABORATORIES (...Dr Ajay Kumar Tiwari
Fundamental knowledge on pharmaceutical
product development and translation from laboratory to market.
Quality management systems: Quality management & Certifications.
1. Introduction to NABL
2. NABL and ISO Principles
3. Need of NABL
4. Recognition of NABL in International Level
5. Scope of NABL
6. Advantages of NABL
How to Prepare for an FDA Inspection and Respond to FDA 483's / Warning LettersGreenlight Guru
How long has it been since your last FDA inspection?
You know FDA is technically mandated to inspect any company with class II or class III products every two years (and inspections have been on the rise particularly for foreign / outside the US firms).
If FDA called tomorrow to announce their plans to visit your facility next week would you be prepared?
Even the most prepared companies still often find themselves receiving 483 observations.
Then you must act swiftly and effectively to avoid that observation escalating to a warning letter.
But what exactly do you do?
How do you respond to FDA 483 observations and/or warning letters?
greenlight.guru founder and VP QA/RA, Jon Speer, has been through his fair share of FDA inspections over the course of his 17+ year career in the medical device industry and has helped many of companies respond to 483 observations and warning letters along the way.
In this free, 60 minutes webinar, Jon will be sharing his most effective tips on how to avoid 483’s and warning letters in the first place along with a step-by-step guide to responding the them if you do happen to receive either.
(You can view the full webinar here: http://www.greenlight.guru/webinar/fda-483-warning-letter-response)
Specifically you'll learn:
What you should be doing to always be prepared for an FDA inspection
How to help prep your team before an FDA inspection
The top 7 reasons FDA issued medical device companies 483 observations and warning letters in FY2015
Tips you can implement today to mitigate your risk of getting 483’s and warning letters
What you need to do before responding to a 483 to minimize the damage (and avoid the common pitfalls)
Best practices for responding to FDA 483 and warning letter (including a free response template)
The differences in responding to a 483 observation vs. a warning letter
What to expect from FDA after submitting your response
The pharmaceutical Quality by Design is a systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management. Quality by Design is emerging to enhance the assurance of safe, effective drug supply to the consumer, and also offers promise to significantly improve manufacturing quality performance
A case study - Implementation of smart test practices improves test coverage by 50% and adherence to regulatory compliance in all product releases enables STAG to gain
the trust and assist in all FDA audit of a leading compliance eLearning solutions provider.
Qms NATIONAL ACCREDITATION BOARD FOR TESTING AND CALIBRATION LABORATORIES (...Dr Ajay Kumar Tiwari
Fundamental knowledge on pharmaceutical
product development and translation from laboratory to market.
Quality management systems: Quality management & Certifications.
1. Introduction to NABL
2. NABL and ISO Principles
3. Need of NABL
4. Recognition of NABL in International Level
5. Scope of NABL
6. Advantages of NABL
How to Prepare for an FDA Inspection and Respond to FDA 483's / Warning LettersGreenlight Guru
How long has it been since your last FDA inspection?
You know FDA is technically mandated to inspect any company with class II or class III products every two years (and inspections have been on the rise particularly for foreign / outside the US firms).
If FDA called tomorrow to announce their plans to visit your facility next week would you be prepared?
Even the most prepared companies still often find themselves receiving 483 observations.
Then you must act swiftly and effectively to avoid that observation escalating to a warning letter.
But what exactly do you do?
How do you respond to FDA 483 observations and/or warning letters?
greenlight.guru founder and VP QA/RA, Jon Speer, has been through his fair share of FDA inspections over the course of his 17+ year career in the medical device industry and has helped many of companies respond to 483 observations and warning letters along the way.
In this free, 60 minutes webinar, Jon will be sharing his most effective tips on how to avoid 483’s and warning letters in the first place along with a step-by-step guide to responding the them if you do happen to receive either.
(You can view the full webinar here: http://www.greenlight.guru/webinar/fda-483-warning-letter-response)
Specifically you'll learn:
What you should be doing to always be prepared for an FDA inspection
How to help prep your team before an FDA inspection
The top 7 reasons FDA issued medical device companies 483 observations and warning letters in FY2015
Tips you can implement today to mitigate your risk of getting 483’s and warning letters
What you need to do before responding to a 483 to minimize the damage (and avoid the common pitfalls)
Best practices for responding to FDA 483 and warning letter (including a free response template)
The differences in responding to a 483 observation vs. a warning letter
What to expect from FDA after submitting your response
The pharmaceutical Quality by Design is a systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management. Quality by Design is emerging to enhance the assurance of safe, effective drug supply to the consumer, and also offers promise to significantly improve manufacturing quality performance
SongwritingTips.org shares 5 songwriting tips on how to write a song. The 1st songwriting tips focuses on what a song really is. This sets the stage for any eager songwriter to embark on the journey of songwriting. Various songwriting tips were also discussed, including song structure and attitude of the songwriter.
George A. Burdock, Ph.D., President of Burdock Group Consultants gives a pre-conference symposium at the Institute of Technologists (IFT) Convention on food safety and regulations of the dietary supplement industry, with a focus on sports nutrition.
Music 2.0 - The Future of Music - Start in Brazil? Feira Musica 2009 Gerd Leo...Gerd Leonhard
My presentation on the Future of Music, from Feira Musica 2009, in Recife Brazil. See more at http://www.mediafuturist.com/2009/12/music-20-my-presentation-at-feira-musica-in-recife.html
At GVK BIO, the independent Quality Assurance (QA) unit conducts different types of audits of services regularly. The QA team ensures that the services delivered are of high quality.
Description:
This course will provide participants with a thorough understanding of the requirements of process validation for both small molecule (pharmaceuticals) and Biologic products. They will learn how to establish an effective process validation system and integrate it with other systems such as Risk Management, Corrective and Preventive Action and Supplier Management.
Participants will learn how to develop rigorous protocols and reports, as well as create monitoring programs to ensure that defined critical parameters remain in control. The course will also review validation requirements for systems that generate electronic signatures and records as most new processes have this capability.
In a welcome move, the Pharmacy Council of India has recently re-structured the syllabus of the
Bachelor of Pharmacy course. In the effort to make the content more relevant to the practice of
pharmacy in its current form, we now find new, important subjects introduced, and Pharmaceutical
Quality Assurance is one of them.
GVK Biosciences (GVK BIO) Clinical Research division has an independent Quality Assurance (QA) unit which conducts audits of services of all business lines within the division on a routine basis to ensure delivery of quality services. The Clinical Research QA staff report
to the Director-QA, GVK BIO who in turn reports to the CEO of GVK BIO
Max Neeman International is India’s leading contract research organization providing full range of clinical development services to small, mid-size and global pharmaceutical, biotech and medical device companies.